GC Cell Obtains License for Management of Human Cells, etc. ... "Expanding CDMO"

[Image source=Yonhap News]

[Asia Economy, reporter Seo Sojung] GC Cell (CEO Lee Deukjoo) announced on March 2 that it has become the first advanced biopharmaceutical manufacturing company in Korea to obtain a license for the management of human cells, etc.

The license for the management of human cells, etc. was newly established following the enforcement of the “Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals.” This license is required in order to collect, process, and supply human cells and other materials that serve as raw materials for advanced biopharmaceuticals.

For cell therapies, since the raw materials must be extracted from human or other cells or tissues, a separate license for the management of human cells, etc. is required in addition to the advanced biopharmaceutical manufacturing license for contract manufacturing of cell therapies.

Lee Deukjoo, CEO of GC Cell, stated, "With this license for the management of human cells, etc., we believe we have gained an edge in the domestic contract development and manufacturing organization (CDMO) business for cell therapies faster than any other Korean company." He added, "If we leverage the expertise we have accumulated through the approval, production, and sales of cell therapies, we will be highly competitive in the specialized CDMO business for cell therapies."

This content was produced with the assistance of AI translation services.